1. V.A.-O. Anagnostou, N. Niknafs, K. Marrone, D.C. Bruhm, J.R. White, J. Naidoo, et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. (2662-1347 (Electronic)).
2. Q. Mao, W. Xia, G. Dong, S. Chen, A. Wang, G. Jin, et al. A nomogram to predict the survival of stage IIIA-N2 non-small cell lung cancer after surgery. (1097-685X (Electronic)).
3. M. Chiu, M.B. Lipka, P. Bhateja, P. Fu, A. Dowlati, A detailed smoking history and determination of MYC status predict response to checkpoint inhibitors in advanced non-small cell lung cancer. (2218-6751 (Print)).
4. T.A. Chan, M. Yarchoan, E. Jaffee, C. Swanton, S.A. Quezada, A. Stenzinger, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. (1569-8041 (Electronic)).
5. J.F. Gainor, H. Rizvi, E. Jimenez Aguilar, F. Skoulidis, B.Y. Yeap, J. Naidoo, et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light,and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. (1569-8041 (Electronic)).